Table 2 Treatment outcomes on day 28, according to treatment received (Placebo or chloroquine).

From: In-Vivo Efficacy of Chloroquine to Clear Asymptomatic Infections in Mozambican Adults: A Randomized, Placebo-controlled Trial with Implications for Elimination Strategies

Variable

Placebo

CQ

p value

N = 27

N = 52

ACPRa (uncorrected) n

4

42

<0.001*

ETFb n

11

0

<0.001*

LCFc n

0

0

NA

LPFd n

9

7

0.037**

New infections (with PCR) n

8

1

0.034

Recrudescences (with PCR) n

1

1

 

No treatment outcome: loss to follow-up or missing or inconclusive PCR results

9

12

NA

ATPe day-28 efficacy (PCR-uncorrected) n/N (95%CI) by optic microscopy

4/22 (18.2%) [2.1–34.3]

42/47 (89.4%) [80.5–98.2]

<0.001*

ATP day-28 efficacy (PCR-corrected) n/N (95%CI)

4/14 (28.6) [4.9–52.2]

42/47 (89.4%) [80.5–98.2]

<0.001*

  1. aACPR:adequate clinical and parasitological response; bETF: early treatment failure; cLCF: late clinical failure; dLPF: late parasitological failure; eATP: According to protocol; NA: not applicable. *Fisher’s exact test; **Chi-squared test.
Back to article page